Clinical Trials

37 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT02682641 2024-02-26

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

50 enrolled

Lymphoma, Mantle-Cell

NCT02471391 2023-08-21

AIM

37 enrolled

Lymphoma, Mantle-Cell

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

Phase 1/2 Unknown

20 enrolled

Waldenstrom Macroglobulinemia, Neoplasms

NCT03280160 2022-09-16

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04514393 2022-04-07

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

33 enrolled

Lymphoma, Non-Hodgkin

NCT02689869 2021-05-07

Alternative

98 enrolled

Indolent Non-Hodgkin Lymphoma

NCT03949062 2021-02-17

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

128 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04094051 2019-09-18

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Unknown

580 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

72 enrolled

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02991638 2018-04-12

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Phase 3 Unknown

62 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Hepatitis B, Chronic, Lymphoma, Mantle-Cell

NCT02912754 2017-03-13

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Phase 1/2 Unknown

36 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02955628 2017-02-14

RICE-ibrutinib in Relapsed DLBCL

34 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02757040 2016-04-29

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Phase 3 Unknown

70 enrolled